Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
22:35:41 EDT Fri 26 Apr 2024
Enter Symbol
or Name
USA
CA



Z:BEAM.PR.A.CL - BEAM INC - https://beamtx.com/
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
BEAM.PR.A.CL - ZDEFUNCT449.61    529.99  405.02Nov 08-12Mar 2615 min RT 2¢

Recent Trades - All 0 today
Time ETExPriceChangeVolume
     
     
     
     
     
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-03-26 06:30U:BEAMNews ReleaseBeam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
2024-02-28 06:30U:BEAMNews ReleaseBeam Therapeutics to Participate in Upcoming March 2024 Investor Conferences
2024-02-27 06:30U:BEAMNews ReleaseBeam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones
2024-02-05 06:30U:BEAMNews ReleaseBeam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
2024-01-08 06:30U:BEAMNews ReleaseBeam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones
2024-01-02 06:30U:BEAMNews ReleaseBeam Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-14 06:30U:BEAMNews ReleaseBeam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors
2023-11-08 06:30U:BEAMNews ReleaseBeam Therapeutics to Participate in 2023 Jefferies London Healthcare Conference
2023-11-08 06:30U:BEAMNews ReleaseBeam Therapeutics Reports Pipeline and Business Updates and Third Quarter 2023 Financial Results
2023-10-31 06:00U:BEAMNews ReleaseBeam Announces Agreement for Lilly to Acquire Beam ¢ € ™s Opt-In Rights to Verve Therapeutics ¢ € ™ Base Editing Programs for Cardiovascular Disease
2023-10-25 06:30U:BEAMNews ReleaseBeam Therapeutics Presents Preclinical Data Highlighting Utility and Durability of BEAM-301 to Correct a Glycogen Storage Disease Type I Deficiency Disease-Causing Mutation at ESGCT
2023-10-19 08:45U:BEAMNews ReleaseBeam Therapeutics Announces Portfolio Prioritization and Strategic Restructuring Focused on Potential Near-term Value Drivers and Long-term Growth of Precision Genetic Medicines Pipeline
2023-09-07 10:00U:BEAMNews ReleaseBeam Therapeutics Presents Preclinical Data Highlighting Utility of ‚  BEAM-302 to Correct an Alpha-1 Antitrypsin (AAT) Deficiency Disease-Causing Mutation
2023-09-05 06:30U:BEAMNews ReleaseBeam Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of BEAM-201 in Relapsed, Refractory T-ALL/T-LL
2023-08-31 06:30U:BEAMNews ReleaseBeam Therapeutics to Participate in Upcoming September Investor Conferences
2023-08-08 06:30U:BEAMNews ReleaseBeam Therapeutics Reports Pipeline Updates and Second Quarter 2023 Financial Results
2023-05-17 06:30U:BEAMNews ReleaseBeam Therapeutics to Participate in Upcoming May Investor Conferences
2023-05-11 06:30U:BEAMNews ReleaseBeam Therapeutics to Participate in RBC Capital Markets 2023 Global Healthcare Conference
2023-05-10 06:30U:BEAMNews ReleaseBeam Therapeutics Reports Pipeline Updates and First Quarter 2023 Financial Results